Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Retained Earnings of -$269000.0 for Q1 2026, down 141.97% sequentially from $641000.0 in Q4 2025, and down 416.47% YoY from $85000.0 in Q1 2025.
Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Retained Earnings for 12 years, with the latest figure at -$269000.0 in Q1 2026.
- Quarterly Retained Earnings fell 416.47% year-over-year to -$269000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$269000.0 (down 416.47% YoY) and the FY2025 annual result came in at $641000.0, up 100.19% from the prior year.
- Retained Earnings fell to -$269000.0 in Q1 2026 per PTGX's latest filing, from $641000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $641000.0 in Q4 2025 and troughed at -$615.7 million in Q4 2023.
- A 5-year average of -$291.4 million and a median of -$408.4 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings slumped 277664.71% in 2024, then jumped 100.19% in 2025.
- Over 5 years, Retained Earnings stood at -$536.8 million in 2022, then fell by 14.71% to -$615.7 million in 2023, then soared by 44.69% to -$340.5 million in 2024, then surged by 100.19% to $641000.0 in 2025, then sank by 141.97% to -$269000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$269000.0, $641000.0, and -$426.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | -304.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -304.04 Mn |
| Mar 31, 2026 | -269,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | -426.29 Mn |
| Jun 30, 2025 | -15,000.00 |
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | -340.52 Mn |
| Sep 30, 2024 | -472.20 Mn |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -408.40 Mn |
| Dec 31, 2023 | -615.71 Mn |
| Sep 30, 2023 | -170,000.00 |
| Jun 30, 2023 | -608.90 Mn |
| Mar 31, 2023 | -570.50 Mn |
| Dec 31, 2022 | -536.76 Mn |
| Sep 30, 2022 | -502.60 Mn |
| Jun 30, 2022 | -471.33 Mn |
| Mar 31, 2022 | -472,000.00 |
| Dec 31, 2021 | -409.36 Mn |
| Sep 30, 2021 | -372.50 Mn |